ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.38
0.12%
US Tech 100
21,213.60
1.06%
S&P 500
6,086.37
0.61%
US Dollar vs CAD
1.43928
-0.01%
Bitcoin
102,401.58
-1.19%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Innate Pharma (IPH) Share Price

Innate Pharma

Innate Pharma (IPH)

IPH Limited
1.744
-0.006
(-0.34%)
Closed January 22 10:30AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.744
Bid
1.732
Ask
1.772
Volume
43,948
1.74 Day's Range 1.788
1.332 52 Week Range 2.79
Market Cap
554.889M
Previous Close
1.75
Open
1.75
Last Trade
92
@
1.744
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
152,677
Shares Outstanding
318,170,508
Dividend Yield
-
PE Ratio
-73.11
Earnings Per Share (EPS)
-0.02
Revenue
61.64M
Net Profit
-7.57M

About Innate Pharma

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.innate-pharma.com
Headquarters
Marseille, Bouches-du-rhone, Fra
Founded
-
Innate Pharma is listed in the Biological Pds,ex Diagnstics sector of the Euronext with ticker IPH. The last closing price for Innate Pharma was 1.75 €. Over the last year, Innate Pharma shares have traded in a share price range of 1.332 € to 2.79 €.

Innate Pharma currently has 318,170,508 shares outstanding. The market capitalization of Innate Pharma is 556.80 € million. Innate Pharma has a price to earnings ratio (PE ratio) of -73.11.

Ask ADVFN Intelligence (AI)

IPH Latest News

More News

Innate Pharma annonce l’organisation d’une conférence destinée aux analystes et investisseurs pour présenter sa stratégie dans le domaine des conjugués anticorps-médicaments

Innate Pharma présentera IPH4502, son programme conjugué anticorps-médicament (ADC) le plus avancé au stade clinique Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) («...

January 21 2025
Business Wire

Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 31 décembre 2024

Regulatory News: Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH...

January 16 2025
Business Wire

Innate Pharma annonce une stratégie de transformation pour accélérer sa croissance

 Une stratégie axée sur le développement clinique précoce de molécules propriétaires présentant un potentiel en monothérapie : Stimuler l’innovation grâce à la plateforme ANKET® produisant des «...

January 10 2025
Business Wire

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P...

December 20 2024
Business Wire

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas Regulatory News: Innate Pharma SA (Euronext Paris:...

December 09 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.096-5.217391304351.841.841.704744441.74783909DE
4-0.206-10.56410256411.952.021.704875521.82083271DE
120.0341.988304093571.712.491.3321526771.76950332DE
26-0.306-14.92682926832.052.491.332941811.82339464DE
52-0.706-28.81632653062.452.791.332818172.03209283DE
156-1.97-53.0425417343.7143.81.3321331332.63674234DE
260-5.201-74.88840892736.9457.3251.3322459483.78737535DE

IPH - Frequently Asked Questions (FAQ)

What is the current Innate Pharma share price?
The current share price of Innate Pharma is 1.744 €
How many Innate Pharma shares are in issue?
Innate Pharma has 318,170,508 shares in issue
What is the market cap of Innate Pharma?
The market capitalisation of Innate Pharma is EUR 556.8M
What is the 1 year trading range for Innate Pharma share price?
Innate Pharma has traded in the range of 1.332 € to 2.79 € during the past year
What is the PE ratio of Innate Pharma?
The price to earnings ratio of Innate Pharma is -73.11
What is the cash to sales ratio of Innate Pharma?
The cash to sales ratio of Innate Pharma is 8.98
What is the reporting currency for Innate Pharma?
Innate Pharma reports financial results in EUR
What is the latest annual turnover for Innate Pharma?
The latest annual turnover of Innate Pharma is EUR 61.64M
What is the latest annual profit for Innate Pharma?
The latest annual profit of Innate Pharma is EUR -7.57M
What is the registered address of Innate Pharma?
The registered address for Innate Pharma is 117 AVENUE DE LUMINY, BP 30191, MARSEILLE, BOUCHES-DU-RHONE, 13009
What is the Innate Pharma website address?
The website address for Innate Pharma is www.innate-pharma.com
Which industry sector does Innate Pharma operate in?
Innate Pharma operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ALMASMastrad
0.0218 €
(122.45%)
24.21M
MLAATAzorean Tech
0.16 €
(60.00%)
1.05k
CDUConduril Engenharia SA
24.60 €
(30.16%)
150
ALNMRNamR SA
0.1745 €
(29.74%)
46.73k
ALSPWSpineway
0.129 €
(28.87%)
960.57k
HYPDSHipay Group DS
0.0002 €
(-98.18%)
115.57k
MLWEYWeya
0.015 €
(-42.31%)
30.9k
DMSBSDiagnostic Medical Systems
0.0045 €
(-35.71%)
7.54k
DRVDSDrone Volt DS
0.0007 €
(-22.22%)
143.64k
POXELPoxel
0.31 €
(-20.61%)
2.9M
ATOAtos SE
0.0021 €
(-4.55%)
914.96M
BCPBanco Comercial Portugues SA
0.5092 €
(-0.62%)
72.88M
ALVERVergnet
0.0016 €
(14.29%)
65.36M
ALMASMastrad
0.021 €
(114.29%)
31.14M
ALCYBCybergun
0.0002 €
(100.00%)
18.07M

Discussion

View Full Feed
jour_trader jour_trader 5 minutes ago
Minutes posted from call, but behind a paywall. 

https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al
ELTP
ace65 ace65 10 minutes ago
When the pigs at the trough get their fill we will have a
HMBL type run.
And the pause of ongoing dilution of course.
HMBL
Dumb&dumber4long Dumb&dumber4long 11 minutes ago
Let’s focus on TNXP, stick politics somewhere else & other subjects too.
TNXP
22rover 22rover 11 minutes ago
It's important to remember that legacy holders have invested at or above 0.18 cents. If they are not following sidechannel’s progress, the reality they see is a thinly traded penny stock lingering near its all-time lows.

They phone their broker to sell the stock. Broker says, yeah, i
SDCH
pegs1 pegs1 12 minutes ago
I think it’s very unprofessional for management to not inform investors of the closing of the lab including departure of scientists! This just continues to be full of surprises ……
CRTG
gp22 gp22 14 minutes ago
ASNS: AI infrastructure stocks are getting hot coming off the massive $ORCL AI Infrastucture deal just announced.
$ASNS the cheapest microfloat AI Infrastructure stock. Top management. Starting to rip. Has recent upgrade from highly regarded Litchfield. Do not miss $ASNS.
$ASNS has 6K
ASNS BFAI ORCL
gp22 gp22 15 minutes ago
ASNS: AI infrastructure stocks are getting hot coming off the massive $ORCL AI Infrastucture deal just announced.
$ASNS the cheapest microfloat AI Infrastructure stock. Top management. Starting to rip. Has recent upgrade from highly regarded Litchfield. Do not miss $ASNS.
$ASNS has 6K
ASNS BFAI ORCL
gp22 gp22 15 minutes ago
ASNS: AI infrastructure stocks are getting hot coming off the massive $ORCL AI Infrastucture deal just announced.
$ASNS the cheapest microfloat AI Infrastructure stock. Top management. Starting to rip. Has recent upgrade from highly regarded Litchfield. Do not miss $ASNS.
$ASNS has 6K
ASNS BFAI ORCL
SkyLimit2022 SkyLimit2022 18 minutes ago
suit,

Thanks for posting the MHRA link!
https://investorshub.advfn.com/uimage/uploads/2024/10/21/zqal[200.gif
https://investorshub.advfn.com/uimage/uploads/2024/10/24/nqdtigiphy.gif

That’s exactly the kind of regulatory support that Advent has provided wh
NWBO
noradio noradio 18 minutes ago
Pm'd
DBMM
AlwaysOptimistic AlwaysOptimistic 19 minutes ago
I agree with you NorCal. Either the current mgt delivers financing this year or just sell the mine as you suggested to a large mining co that can deliver results. Many of us are stuck with shares that have fallen to lows that are not even worth selling. Would like to see a rebound and recoup our or
NB
The GidDy uP Kid The GidDy uP Kid 22 minutes ago
CNSP, readying for a Bullish Hammer tomorrow… 
https://schrts.co/cBIMqiew
CNSP
The GidDy uP Kid The GidDy uP Kid 22 minutes ago
CNSP, readying for a Bullish Hammer tomorrow… 
https://schrts.co/cBIMqiew
CNSP
The GidDy uP Kid The GidDy uP Kid 23 minutes ago
CNSP, readying for a Bullish Hammer tomorrow… 
https://schrts.co/cBIMqiew
CNSP
harry crumb harry crumb 24 minutes ago
Lets see 1.50 tomorrow or lower boys! Jam it at open! Lets roll $$$$$$
ILLR
XMaster2023 XMaster2023 25 minutes ago
Theory, Approval of DCVax is near!
NWBO
Plato_ Plato_ 26 minutes ago
Yup, that's the way I understand it. Whether the contract is paid up front or on performance, the revenue is recognized when earned and deferred revenue is reduced to match. Good example with the labor-based contract. Same principle. You make a good point about the intellectual property. If this is
GDVM
boi568 boi568 26 minutes ago
Statutes and regulations will always trump guidances, assuming the statutes or regulations address the issue the guidance is addressing. The reason agencies issue guidance is because the statutes and regulations haven't addressed the issue.

So, if you can find an FDA statute or regula
AVXL
boi568 boi568 26 minutes ago
Statutes and regulations will always trump guidances, assuming the statutes or regulations address the issue the guidance is addressing. The reason agencies issue guidance is because the statutes and regulations haven't addressed the issue.

So, if you can find an FDA statute or regula
AVXL
3331 3331 27 minutes ago
3331 has been restricted to one post per day:

BIEL HITS COPPER "IN THE BLINK OF AN EYE" WHEN THE FOLLOWING OCCURS!

pps > .001 after management drops some positive hints. The Golden Cross (already achieved) and Blue Sky Breakout will get the technicians/chartists attenti
QUBT SERV
theorysuit theorysuit 28 minutes ago
https://cms.mhra.gov.uk/mhra/mia/uk-miaimp-54923

Oh you are talking about this MIA. Unfortunately, i only see ADVENT on this MIA. No sight of NWBO at all. Like i said congrats to LP not NWBO.


https://find-and-update.company-information.service.gov.uk/company
NWBO
HomerRomer HomerRomer 29 minutes ago
This is a response to Missling’s LinkedIn post by a VERY educated and qualified senior vice president of Red Nucleus who manages and provides strategic oversight and tactical back up for clinical teams.  He seems to think Blarcamesine  could likely work better than the study results show. 
AVXL

Your Recent History

EU
IPH
Innate Pharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads